Phase 2 T-cell Lymphoma Clinical Trials
46 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 46 trials
Recruiting
Phase 1Phase 2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1Phase 2
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Aggressive NK-cell LeukemiaLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell Lymphoma+10 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting
Phase 2
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
T-cell Lymphoma
Yale University32 enrolled2 locationsNCT05313243
Recruiting
Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Lymphoproliferative DisordersImmune System DiseasesPeripheral T-cell Lymphomas
National Cancer Institute (NCI)330 enrolled2 locationsNCT03922724
Recruiting
Phase 2
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedFollicular Helper T-Cell Lymphoma
City of Hope Medical Center25 enrolled1 locationNCT07293403
Recruiting
Phase 1Phase 2
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Hodgkin LymphomaNon-Hodgkin LymphomaLymphoma+4 more
AstraZeneca161 enrolled35 locationsNCT06137144
Recruiting
Phase 2
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Newly Diagnosed Peripheral T-cell Lymphoma
Liling Zhang36 enrolled1 locationNCT05976997
Recruiting
Phase 1Phase 2
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
T-cell LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPTCL
Peking University People's Hospital30 enrolled1 locationNCT06874946
Recruiting
Phase 2
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
St. Jude Children's Research Hospital100 enrolled3 locationsNCT06390319
Recruiting
Phase 1Phase 2
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
T-cell Lymphomas
Dizal Pharmaceuticals165 enrolled12 locationsNCT07496229
Recruiting
Phase 2
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
T-cell LymphomaT-cell Prolymphocytic LeukemiaLymphoma, T-Cell+5 more
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting
Phase 2
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Sun Yat-sen University84 enrolled1 locationNCT06583083
Recruiting
Phase 2
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
T-cell Lymphoma
Yale University22 enrolled2 locationsNCT05996185
Recruiting
Phase 2
A Study of Enasidenib in People With T-Cell Lymphoma
T-cell Lymphoma
Memorial Sloan Kettering Cancer Center25 enrolled8 locationsNCT06756308
Recruiting
Phase 2
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Fudan University210 enrolled7 locationsNCT06314334
Recruiting
Phase 2
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
Natural Killer/T-cell Lymphoma
Ruijin Hospital47 enrolled1 locationNCT07380984
Recruiting
Phase 1Phase 2
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Ovarian CancerMelanomaT-cell Lymphoma+1 more
BioInvent International AB176 enrolled25 locationsNCT04752826
Recruiting
Phase 1Phase 2
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Haihe Biopharma Co., Ltd.100 enrolled1 locationNCT06909877
Recruiting
Phase 2
Phase II Clinical Trial of Drug Combinations Guided by Ex-vivo Testing in Patients With Relapsed/Refractory T-cell Lymphoma (COMBINEX-T)
Relapsed/Refractory Peripheral T-cell Lymphoma (RR PTCL)
National University Hospital Singapore36 enrolled1 locationACTRN12626000088347
Recruiting
Phase 2
Amping up With PemJAK
Non-Hodgkin LymphomaPeripheral T Cell LymphomaPrimary Mediastinal B Cell Lymphoma+5 more
Seda S. Tolu53 enrolled1 locationNCT07283822